Tezspire▼ (tezepelumab) helpful resources

This is a non-promotional website produced and funded by AstraZeneca, intended for UK patients who have been prescribed TEZSPIRE▼ (tezepelumab)

Coming soon: We are currently updating this website with all relevant information for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). Please bear with us! You can access Tezspire CRSwNP resources here.

For UK patients, and their caregivers, aged 12 and over who have been prescribed Tezspire (tezepelumab) for severe uncontrolled asthma

For UK patients, and their caregivers, aged 18 and over who have been prescribed Tezspire (tezepelumab) for severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

For more information read the patient information leaflet accessible here

For UK patients, and their caregivers, aged 12 and over who have been prescribed Tezspire (tezepelumab) for severe uncontrolled asthma

For UK patients, and their caregivers, aged 18 and over who have been prescribed Tezspire (tezepelumab) for severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Click to access the Tezspire Patient Information Leaflet (PIL) relevant to you:

Helpful videos

Tezspire pre-filled pen instructional video

Tezspire pre-filled syringe  instructional video

Click here for additional support with self-administration

Reporting side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk https://yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get as advised above.

Abbreviation

CRSwNP: Chronic Rhinosinusitis with Nasal Polyps

GB-75789 | August 2026

This is a non-promotional website produced and funded by AstraZeneca.

This site is intended to complement, not replace, the 'Instructions for Use' and 'Patient Information Leaflet' (found in your carton or linked at the top of the page). Refer to these materials for additional important information.

If you have any questions or concerns about your treatment, you should always talk to your healthcare team.

Please see the information in the box above for details on how to report any side effects you may be experiencing.